“An Experimental and Clinical Study on Swarnaprashan to Establish its Safety, antimicrobial activity and to Assess its Immunogenicity Effect after BCG Vaccinationâ€
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- IMPROVEMENT IN immunity and overall health condition due to reduction in number of episodes of illness and safety of drug
研究概览
简要总结
It will be a singlearm open label Exploratory study including a totalof 30 patients of1-15years, irrespective of sex suffering with recurrent illness will be selected to assess themorbidity incidence during the study period. The Swarnaprashanwith Swarna bhasma -15mg, Madhu 2 mlof and 1 ml of Ghrita, will be given once a dayfor 1 month in early hours of morning (8 to 10 a.m.) after gettingwritten informed consent from the parents. All the cases will be gathered from the Kaumarbhritya - OPDor IPD; S.S. Hospital, IMS, BHU after assessing the following exclusion andinclusion criteria -
Inclusioncriteria:
a)Age between 1to 15 years
b)Having history of repeated respiratory or any other recurrent disorderirrespective to associated congenital, hereditary or developmental/nutritionaldisorders
c)Period of drug administration - asymptomatic Phase
ExclusionCriteria:
a)Neonates and infants <1year and 16 or more than 16 years
b)During any symptomatic illness
c)Suffering from degenerative neurological, IEM, etc.
Investigations:
Thefollowing investigations will be prescribed before and after 1month of drugadministration
CBC,GBP, LFT, RFT, ESR, Urine,stool Routine, Others–disease specific like swab, urine, stool forculture and sensitivity, CT,MRI,X-ray
Follow up:: Thepatients will be called for follow up at an interval of 15 days for 3 monthsand as per the proforma theepisodes of respiratory or any other illness would be recorded.
Adverse effect:anyuntoward effects duringthe study willalso be recorded and treatment would be stopped in-between and the case wouldbe dropped and specific treatment will be given to relieve the symptoms.
Statistical Analysis:relevant statistical formula will be used for analysis of data.
Thenall Data shall be concluded after categorizing into particular specific part ofthe study as experimental, animal, clinical study with the reasoning on theparticular observation with statistical significance.
Fordata analysis SSPE software will be used in collaboration of Dep’t of Statistics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Other
- 盲法
- Open Label
入排标准
- 年龄范围
- 1.00 Year(s) 至 15.00 Year(s)(—)
- 性别
- All
入选标准
- •a) Age between 1to 15 years b) Having history of repeated respiratory or any other recurrent disorder irrespective to associated congenital, hereditary or developmental/nutritional disorders c) Period of drug administration.
- •asymptomatic Phase.
排除标准
- •a) Neonates and infants <1year and 16 or more than 16 years b) During any symptomatic illness c) Suffering from degenerative neurological, IEM, etc.
结局指标
主要结局
IMPROVEMENT IN immunity and overall health condition due to reduction in number of episodes of illness and safety of drug
时间窗: after one month of administration of drug
次要结局
- IMPROVEMENT IN immunity and overall health condition due to reduction in number of episodes of illness(after 2months of follow up)
